Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...

EARLY-STAGE bladder cancer can be effectively diagnosed using unprocessed urine samples at the point of care, achieving 90% ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

· Tempus AI, Inc. (NASDAQ: TEM) started 2025 announcing the National Launch of its FDA -approved xT CDx Test, a 648-gene next-generation sequencing test for solid tumor profiling, which includes ...

A 6.5-month-old boy with the rare inherited urea cycle disorder ornithine transcarbamylase (OTC) deficiency has responded positively in a targeted in vivo gene editing trial, in which a correct copy ...

Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating ...

The bladder cancer test developer says it will go to court if an unfavourable US reimbursement decision is not reversed.

Bladder cancer is one of the most common malignant tumors in urinary system, and the treatment faces huge challenges.

A combination therapy of two drugs — a statin and a protein inhibitor — may help suppress the creation and growth of tumors ...